Cancer is a disease that is thought to begin as a result of one or more mutations in the DNA of our cells. In the past, pancreatic cancer researchers typically concentrated on a limited number of mutations on perhaps four to eight known gene culprits. . Now, a comprehensive listing of genetic mutations in cancer of the pancreas (ductal adenocarcinoma of the pancreas) has been published in the journal Nature on November 15, 2012 by a large consortium of Australian, North American and European researchers (including two of our Pancreatica Science Board members, Drs. Hruban and Tempero).
This study is a milestone in pancreatic cancer research that looked at tumors in 142 pancreatic cancer patients. Intensive analysis of 99 tumors found 16 significantly mutated genes with 2,016 identified mutations and many other genetic variations. This included alterations not previously understood to be involved in pancreatic cancer. This new information and understanding gained directly from human subjects (for the first time) looks to open a doorway to an expanded era in treatment targets in the fight against pancreatic cancer.
Dale O’Brien, MD
Congratulations to our Seattle fundraisers who took part in the Amica Seattle Marathon, Half Marathon or 5K last Sunday!
It was a blustery rainy day but everyone pushed themselves and we can’t thank you enough for your incredible participation in the fight against pancreatic cancer!
One of our favorite pancreatic cancer researchers, Dr. Daniel Von Hoff of TGen in Arizona – together with researchers from the Virginia G Piper Cancer Center – is reporting encouraging clinical trials results for those with advanced pancreatic cancer (ductal adenocarcinoma of the pancreas) treated with a combination of Abraxane plus gemcitabine. Neufachivife . This MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study as chaired by Dr. Von Hoff is a part of a multi-center international investigation of 861 pancreatic cancer patients with results that are expected to be reported out in greater detail at the ASCO GI symposium in San Francisco in January 24-26, 2013. Dr. Von Hoff was a key researcher on the early development of gemcitabine.
Dale O’Brien, MD